Long-suffering biotech investors might be in for a treat as the SPDR S&P Biotech exchange begins to show signs of renewed ...

Glenmark Pharmaceuticals Ltd.’s licensing pact with AbbVie Inc. for its blood cancer drug is boosting optimism over Indian ...

Ultragenyx and partner Mereo BioPharma’s brittle bone disease trial will continue. Investors had wanted data good enough to ...

Biotech stumbled in FY25, but we didn’t. HB Biotechnology kept its footing and delivered 23% outperformance in a tough market ...

Merck has reached an agreement to acquire British pharmaceutical company Verona Pharma in a deal worth around $10 billion, ...

This stock used to be a highflyer but has struggled in recent years as demand waned for its flagship product. Though Moderna ...

Love her or hate her, Cathie Wood is a true maverick who’s made a name finding tomorrow’s big disruptors long before anyone ...

Klotho shares have soared more than 1000% over the past three months on promising results and breakthrough hopes.

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortress Biotech (FBIO) could be a great choice. It is one of the several stocks ...

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

Amgen has transitioned into a mature, cash-generating pharma-biotech hybrid. Click here to find out why AMGN stock is a Buy.

Investing.com -- PDS Biotechnology Corp (NASDAQ: PDSB) stock rose 3.8% after the company announced that its clinical trial for metastatic colorectal cancer treatment has met pre-set criteria for ...